Compugen reports Q2 2026 financial results and clinical progress
MAIA-ovarian interim PFS data expected by Q1 2027; AstraZeneca presented rilvegostomig OS data; Gilead-partnered GS-0321 Phase 1 progresses; cash runway into 2029.
See the latest news and media coverage for Compugen. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing immuno-oncology therapeutics
cgen.comLast updated
In short: Compugen reported Q2 2026 results and advanced its clinical pipeline while maintaining a cash runway extending into 2029.
MAIA-ovarian interim PFS data expected by Q1 2027; AstraZeneca presented rilvegostomig OS data; Gilead-partnered GS-0321 Phase 1 progresses; cash runway into 2029.
The company will host a conference call and webcast at 8:30 AM ET to review the results and provide a corporate update.
Cash runway extends into 2029; COM701 MAIA-ovarian trial actively enrolling; partners AstraZeneca and Gilead advancing programs.
Strengthened financial position via AstraZeneca deal and advanced clinical pipeline with COM701 and GS-0321.
Compugen Ltd. announced its financial results for the second quarter and first half ended June 30, 2026. For the second quarter, the...
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities...
Compugen (CGEN) delivered earnings and revenue surprises of 0.00% and -3.63%, respectively, for the...
Compugen () has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks. Unlock powerful investing tools...
Track Compugen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Compugen and other trending companies.